For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Spravato is made from esketamine, one of two mirror-image molecules ... on Spravato also receive an oral antidepressant. Now, the FDA says the drug can be used on its own. The decision came ...

The FDA said this is the first time esketamine was approved for any use. The agency approved ketamine, a related drug and an anesthetic, in 1970. Ketamine, also known as “Special K,” a party ...

Long-term, heavy ketamine use is associated with memory problems, depression and anxiety. The drug may also cause ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...

They receive esketamine at a certified doctor’s office or in a clinic, where a health care provider watches over them for at least two hours after the dose. (When the FDA first approved ...

“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...

If it is then approved by the FDA, the drug -- called esketamine -- may provide a new option for patients with major depressive disorder who have tried at least two other antidepressants without ...

It is FDA-approved as an intravenous or intramuscular injection solution as part of general anesthesia. It is a mixture of two mirror-image molecules, arketamine and esketamine. Another approved ...